Beyond the Usual Suspects: Ischemic Stroke from Neurosyphilis in a Young Patient

encephalitis antibody panels.Four published cases of EPC following alemtuzumab for multiple sclerosis had responded to immune modulating treatments.The patient received five days of high dose methylprednisolone, IVIG, plasmapheresis and rituximab which led to rapid seizures resolution and marked improvement in hemiparesis, aphasia and EEG abnormalities.He was found to have a likely pathogenic variant in MT-TF mitochondrial gene. ConclusionsTo our knowledge this is the first report of EPC following alemtuzumab in a child, and the first report of EPC following alemtuzumab used for immunosuppression induction for solid organ transplant.The response to immunotherapy suggests an autoimmune etiology of EPC in our patient.MT-FT variant might have contributed to decreased seizure threshold.This case adds to the literature of EPC in patients receiving alemtuzumab and expands its clinical setting.Study Supported By: N/A.Disclosure: